2nd Quarter - Report

THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION

Firm
Client
Income
—
Expenses
$120,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Advise on standards setting verification, overseas programs, and quality medicines - activities related to drugs, dietary supplements, food ingredients, and compounding S. 469, the Affordable and Safe Prescription Drug Importation Act; provisions related to importation. FY 2018 HHS Budget issues; provisions affecting the FDA. User fee agreements H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017 USP Medicare Model Guidelines and USP Drug Classification Implementation of Public Law No. 115-31; provisions relating to compounding

LobbyistCovered position, as disclosed
CARRIE HARNEY —

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2871 (115th), S. 469 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.